HIV Prevention Study Using PrEP Should Be Replicated After Success In Australia’s NSW, Researchers Say

The Guardian: Groundbreaking Australian HIV trial should be replicated, researchers say
“High-income countries with people at high risk of HIV should replicate a groundbreaking trial in Australia, which has seen new infections [among men who have sex with men in New South Wales] fall by 25 percent in one year following the rapid rollout of free HIV medication, researchers say. … Professor Andrew Grulich, from the Kirby Institute at UNSW Sydney, led a study that followed … gay and bisexual men … Only two of the men acquired HIV, and neither of those had been taking PrEP as prescribed…” (Davey, 10/17).

Reuters Health: HIV prevention drugs could dramatically cut new infections
“… ‘(This is) a really important study because it documents the benefit of HIV prevention pills at a population level,’ said Dr. Jeffrey D. Klausner of the University of California, Los Angeles, who wasn’t involved in the new research’…” (Carroll, 10/17).

Additional coverage of the PrEP study is available from Bloomberg, CNN, NBC News, and STAT.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.